GSC announces positive results from pharmacogenomic study
Green Shield Canada and HBM+, its health benefit managements solutions division, have announced the high-level results of a previously announced pharmacogenomics clinical trial study examining whether drug treatment can be improved using information about a person’s genetic profile.
“We undertook this study because there were substantial gaps in knowledge regarding the downstream impact of pharmacogenomic testing on patients, but the results confirm that it can be a difference-maker for those suffering with major mental health conditions,” said David Willows, GSC’s EVP, Digital, Innovation and Brand Experience.
The study was a single-blinded randomized controlled trial, which followed over 200 outpatients diagnosed with major mental health conditions such as depression and anxiety.
Each participant was randomly sorted into either a control group, where drug optimization was conducted purely based on a pharmacist’s clinical judgment, or an experimental group where a pharmacist administered pharmacogenetics-guided treatment.
Validated psychiatric instruments – including the Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder Scale (GAD-7) and Sheehan Disability Scale (SDS) – were used to evaluate patient response.
Over a six-month trial period, participants in the pharmacogenomics-guided cohort reported significantly greater improvements. Compared to the control group, they showed better recovery with respect to depression severity (36% improvement from baseline for the pharmacogenomics-guided group vs. 16% for the control group), anxiety (41% vs. 23%), and disability (44% vs. 18%).
“Moving forward, the study data presents a compelling picture of the important role that pharmacogenomics can play in optimizing drug therapy and helping pharmacists and physicians to improve patient health,” Willows said.
Read the original article at https://www.lifehealthpro.ca/rss/